Fate Therapeutics, Inc. received a $15 million grant.

The RECLAIM-LN Phase 2 clinical trial is expected to enroll 53 participants.

FT819 is the off-the-shelf CD19-targeting CAR T-cell product candidate tied to the trial, and the trial’s primary endpoint is the proportion of participants achieving complete renal response at Week 26.

Fate Therapeutics, Inc. is headquartered in San Diego, CA.

Highlights

  • Fate Therapeutics, Inc. is based in San Diego, CA.
  • FT819 is an off-the-shelf CD19-targeting CAR T-cell product candidate.
  • The RECLAIM-LN Phase 2 clinical trial has a primary endpoint of complete renal response at Week 26.